Dr. Sangeeta Tiwari, Ph.D.
Assistant Professor (Tenure Track)
Department of Biological Sciences
Border Biomedical Research Center (BBRC)
University of Texas at El Paso
El Paso, TX79968, USA
Dr. Tiwari is an infectious disease researcher with a focus on Tuberculosis chemotherapy, bacterial pathogenesis, and host-pathogen interactions. During her research career at the Yale School of Medicine and Albert Einstein College of medicine, she had published several papers in prestigious journals such as a PNAS, Immunity, Science and Nature Immunology, and has successfully filed a collaborative patent. Along with other awards in the Yale School of Medicine and Albert Einstein College of Medicine. Dr. Tiwari had recently received the University of Texas System’s Faculty STARs Program Award. Tuberculosis is a debilitating disease caused by the pathogen Mycobacterium tuberculosis (Mtb). Problem is further worsened with the increase in the number of cases due to HIV and emergence of drug resistant strains. The only available FDA-approved vaccine until now is BCG, and its efficacy varies with age and geographical distribution. This demands urgent need for new TB chemotherapies, shortening existing chemotherapies and new vaccines. To develop new drugs and vaccines it is essential to understand biology of the organism and understanding host-pathogen interface. Our lab works on (1) Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses (2) Vaccines and (3) Understanding of metabolic pathways required for survival and persistence of mycobacteria in the host. Other than that lab is also working on various aspects of Cancer and TB-HIV co-pathogenesis. Dr. Tiwari’s lab will be using multiple techniques involving a combination of molecular biology, biochemistry, genetics, metabolomics, cell biology and immunology to address these questions using cells and mice models. Her passion at UTEP involves developing a better understanding of the host-pathogen interactions, identifying potential new drug targets, vaccine candidates and also initiating active collaboration with other research faculty. We are also interested in focusing on research and collaborations to understand mechanisms involved in HIV-TB coinfections and cancer immunotherapy.